Infliximab in primary Sjögren's syndrome: one-year followup

Arthritis Rheum. 2002 Dec;46(12):3301-3. doi: 10.1002/art.10674.


Objective: To evaluate the safety and efficacy of a maintenance regimen of infliximab in patients with active primary Sjögren's syndrome (SS) over a 1-year period.

Methods: This followup study included 10 of the 16 patients with primary SS who participated in a pilot study. Patients who continued to have symptoms received additional infusions of infliximab for 1 year.

Results: All patients completed the 1-year followup for evaluation of efficacy. After 1 year, a statistically significant decrease in global and local disease manifestations was observed in all 10 patients. Treatment was generally well tolerated, with the main side effect being a mild, self-limited infusion reaction.

Conclusion: Sustained improvement of active primary SS may be possible with infliximab treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Retracted Publication

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Infliximab
  • Pilot Projects
  • Sjogren's Syndrome / drug therapy*
  • Sjogren's Syndrome / physiopathology
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Infliximab